Ali Stunt

Me, on holiday (but still working!) July 2016

The 30th August 2007 was the day I was diagnosed with pancreatic cancer. A disease I hadn’t ever heard of and, at the time, I had no real understanding of what I was about to endure. I had no idea that the survival statistics were so poor and that I was then facing only a 3% chance of surviving beyond five years.

But, survive I have, and more years than many others who have faced the same diagnosis. That’s because I was diagnosed in time for surgery to be possible. My surgery was a distal pancreatectomy and splenectomy where I lost 80% of my pancreas and all of my spleen. Of the two main surgical procedures, mine was the lesser but it still took five hours to perform and several weeks to recover from. I followed this with six months of chemotherapy including two drugs: gemcitabine and cisplatin then a further 5 weeks of chemo-radiotherapy.

 It was nearly a year’s worth of treatment: weekly appointments with the oncologist, then daily appointments at the radiotherapy centre. I was becoming used to a kind of institutionalised lifestyle and the support of my medical team along the way.

Then it all stopped and I began to feel the loss of that support and framework to my life. It was a good thing to rid myself of so many hospital appointments but nevertheless I felt a kind of emptiness which was compounded by an overwhelming sense of what had just happened to me. I suppose had I been a soldier back from Afghanistan, I may have been labelled with Post Traumatic Stress Disorder – something I can really relate to.

However, with the strength that my family and friends have given me, I have been able to cope (more or less) with the impact of the pancreatic cancer diagnosis and the resulting survivor’s guilt and was helped in a major way through my founding of and working at Pancreatic Cancer Action.

My work at the charity is a daily reminder that life isn’t all about me – there are many touched by this disease who are far worse off than I am and it is my life’s work now to try to ensure many more are diagnosed sooner so they too can have the same outcome as me.

I now, more or less, live a normal life, but there are some things that have changed since my surgery. I am insulin dependent diabetic – type 3 – a type I had never heard of (and some doctors are unaware of this type too!). I need to be on permanent antibiotics now I don’t have a spleen, and I can suffer the effects in wintertime of the peripheral neuropathy which is a hangover from my chemotherapy treatment.

I am currently being investigated for new changes to bowel habit and being fast tracked (this time!) for urgent referrals for tests. It is a bittersweet irony that on the anniversary of surviving nine years following pancreatic cancer, I am awaiting the results of a CT scan to see if anything nasty has returned. The fear of this is as real as it has been throughout the past nine years and I guess it is something that will never leave me. Hopefully it will only mean I will now have to take CREON with meals to help me digest food properly – something I have managed to avoid so far!

But I am lucky, I have been here to see my two boys grow up into fine young men, enjoy lots of family holidays to lovely places including Australia, Egypt and Africa, go on walks in the woods with my dogs and to still have the support, love and company of my true best friend, my husband Phil.

As I enter the 10th year of my diagnosis, there is a lot to reflect on and a lot to be thankful for. Next August will mark my 10th anniversary and, statistically, only 1% of us diagnosed with pancreatic cancer ever live that long.

When you’re at the beginning of your ‘journey’ with pancreatic cancer, it almost seems inconceivable that you will hit those milestones and become one of those slim statistics. My husband’s positive attitude and mantra that I was a statistic of one: my disease, my treatments, my outcome. This helped me mentally get through and to believe that I could be one of the 3% (to survive 5 years) and now to believe I will make up one of the 1% to live for 10 and more years. Here’s hoping!

Ali short sig purple2

Ali Stunt

30th August 2016


NEC Health & Wellbeing Show March 2017.png

Ali Stunt and Lucy de’Lemos at the Health & Wellbeing Show, NEC March 7-8 2017

On March 7-8 we exhibited at the Health and Wellbeing at Work show at the NEC in Birmingham. This gave us an opportunity to discuss pancreatic cancer with Occupational Health (OH) professionals from organisations large and small from across the UK.

We stressed the lack of public awareness about pancreatic cancer (70% of the UK population does not know where their pancreas is) and that in the UK, 40% of patients are under the age of 69 and some therefore will be in the workplace.

We talked about our Pancreatic Cancer Aware campaign and its dedicated website and how some of those assets, including videos, can be used on their company intranets and in their internal health and wellbeing emails.

Screenshot 2017-03-09 12.12.48

The Pancreatic Cancer Aware Campaign

We talked about how, by utilising Pancreatic Cancer Action’s comprehensive awareness materials, we can try to improve early diagnosis by making the UK workforce more aware of the disease and its symptoms and risks.

We had an excellent response and have had a lot of requests for literature and for us to visit some of the organisations to talk to their staff. Most Occupational Health professionals told us that they have not ever had an awareness drive on pancreatic cancer and that they would be keen to do so in the future.

This for us is a fantastic opportunity to work with Occupational Health professionals to communicate our messages about pancreatic cancer to their teams and to staff within their organisations.

If you would like us to visit your company to talk about pancreatic cancer or provide your Occupational Health team with pancreatic cancer awareness materials, please get in touch. 

Ali short sig purple2

pre-op-assessmentA recent study by Cancer Research UK*  has found that for all cancers, the number of cancer cases and deaths will increase by 2035 by 42% (cases) and 30% (deaths).

However, what we do see is the rate of incidence for all cancers combined falling in women by 0.11% and in men by 0.03% by 2035 and, for most cancers, the mortality rate is decreasing too. (The age standardised rates describe cancer incidence and mortality with reference to a standard population and accounts for such things as differences in age and composition of the population).

One of the cancers that is bucking that trend in terms of reduced rates of incidence is pancreatic cancer. Instead of seeing rates falling, the rate of incidence of the number of cases is predicted to be up by nearly 5% in women and nearly 7% in men between 2014 and 2035.

The rates of incidence for cancers such as bowel, bladder and lung are predicted to reduce significantly over the same period.

So what does this mean? Well the number of actual cases of pancreatic cancer (which is a different number than the rate at which they occur) is likely to top 15,000 by 2035 and the numbers of actual people dying is predicted to be over 13,000. See the tables below:



That’s a predicted increase of nearly three per cent per year in the number of cases and over two per cent per year for the numbers of people dying from pancreatic cancer.

With an increasing population size and an ageing population, it is not surprising to see that the number of people affected by cancer is increasing over time. What is concerning is that the rate of incidence and mortality for other cancers is predicted to decline by 2035 and in some cases significantly.  One of the exceptions is pancreatic cancer.

And, while the rate of mortality (death) is influenced by the incidence (cases) rate, other factors will influence these numbers such as how successful the healthcare system is in diagnosing and treating the cancer in question.

We know that pancreatic cancer is diagnosed late, when it has already spread to other parts of the body. This, and the fact that we have few treatment options available to patients, means that we will only continue to see increasing death rates from pancreatic cancer to 2035 and beyond. This is unless we see noticeable improvements in diagnosis and treatment which will only happen when we get greater focus on and funding for the disease.

Ali short sig purple2

Ali Stunt

Oct 24th 2016

*All data from: Smittenaar, Petersen & Moitt (2016) Cancer incidence and mortality projections in the UK until 2035. Brit.Journal of Cancer 1-9 DOI:10.1038/bjc.2016.304


Pancreatic Enzymes will now form part of my daily routine

After nine years of managing to avoid it, it has happened to me. It has now been confirmed that I have Pancreatic Exocrine Insufficiency and I am awaiting an appointment with my specialist HPB dietitian to advise me on a prescription of the digestive enzyme drug CREON. This diagnosis is not something that is unusual for those of us who are/have been suffering pancreatic cancer, but what is unusual is that I have not been diagnosed with it before now.


Pancreatic Exocrine Insufficiency (or PEI for short) is where there has been a change in the flow and amount of pancreatic juice (which contains enzymes to break down foods such as fat, protein and carbohydrate). Without enough digestive enzymes, the food can pass through the digestive system without being properly broken down and absorbed.

In my case, they symptoms of this condition included more frequent and looser bowel movements and periods of sudden evacuation (rush to the loo time!), terrible bloating and sometimes debilitating stomach cramping, especially just after I had eaten, plus the odd bout of wind. Some people with PEI will lose weight, but not so in my case. Perhaps it is because my level of PEI is moderate: on the scale at 118.

The test I had was a poo test known as a faecal elastase test. The ranges of normal to moderately or severe insufficiency are below:

  • More than 200 ug Elastase/g stool = Normal
  • 100 to 200 ug Elastase/g stool = Moderate to slight exocrine pancreatic insufficiency
  • Less than 100 ug Elastase/g stool = Severe exocrine pancreatic insufficiency

Now, many people in my position (who have had surgery to remove a pancreatic cancer tumour) will develop PEI from the outset. Others tend to find they either don’t get it at all or, like me, it creeps up on you over time. After my surgery, I was left with around 20% of the head of my pancreas and this has kept going like the clappers for years.

I had noticed the odd change in bowel habit about 18 months ago but, because these were infrequent and had no pattern, I just thought it may be something I was eating that didn’t agree with me. I had always (since my operation) had difficulty digesting red meat and had side effects from eating strong cheeses like Stilton, but removing these foods from my diet seemed to sort the problem. Until recently.

The last 3 months or so have been really trying as my symptoms took a noticeable turn for the worse. To say I have been struggling with day-to-day activities is an understatement. It has been difficult to concentrate and the fear that I may not get to a loo in time has been immense. My coping strategy has been to consume a lot of Imodium and to plan journeys expertly according to where facilities are.

What is interesting is that pancreatic insufficiency may be having an effect on my glycaemic control which could in part explain why, as an insulin dependent diabetic, my blood sugars have been difficult to control over the past year or so.

I am looking forward to starting on the digestive enzymes despite the fact it is yet another drug I have to take and that I will have to remember to take it with any meals and snacks I eat. It is likely that I will have to adopt this for the rest of my life – a small price to pay for surviving pancreatic cancer.


Ali short sig purple2

Ali Stunt

September 2016


PCE JUly 2016 (002)I joined the first formal Board meeting for Pancreatic Cancer Europe (since its new legal status as a not-for profit registered in Brussels) which was held in Liverpool in early July.

I have been a founder member of Pancreatic Cancer Europe (PCE) which is a multi-stakeholder platform made up of clinicians, patient groups, researchers, industry, journalists and EU policy makers. Our aim is to improve diagnosis and care for patients across the EU and to ensure that there are no inequalities in that care no matter where patients reside.

There are four main work streams: Awareness and Diagnosis, Registries, National Support and Research and I am proud to be the lead for the Awareness work and being able to bring some of the knowledge and experience of my work with Pancreatic Cancer Action to PCE.

Funded by pharmaceutical companies Celgene and Shire, we have been in operation since November 2014 and have already produced several documents and awareness materials including a micro site, symptoms posters, 10 key facts and GP leaflets on diagnosing pancreatic cancer.

Thankfully, PCE covers a geographical Europe and not a political one so, being from the UK, my role as a Board member is currently unaffected by the Brexit decision.

Having a legal entity for the organisation is an important step for PCE as it gives it a formal structure and increased credibility and legitimacy within the EU. This foundation will underpin the four work streams (Awareness and Diagnosis, Registries, National Support and Research) and will enable us to apply for funding from a wider group of sponsors than present. It will also enable funding from the EU itself for future projects – all with the aim of improving outcomes for pancreatic cancer patients across the EU and the UK!

For more information on Pancreatic Cancer Europe, visit

We have seen a lot in the press recently about the advances in immunotherapy for many Immunotherapycancers and, in the case of melanoma, with extraordinary results.

We’ve not as yet seen this happen for pancreatic cancer which, so far, has proven difficult to treat with either conventional chemotherapy and/or novel immunotherapy. Some trials of immunotherapy (which targets the body’s immune system to fight the cancer) have failed and, it is believed one of the reasons for this is that pancreatic cancer tumours are cunning in the way they are able to manipulate the immune system to help their own progression.

Our immune system contains many different types of cell, whose job it is to detect and destroy dangerous invaders such as viruses and bacteria in order to prevent serious diseases. What is important is for these cells to also be able to recognise the good bugs, such as healthy bacteria in our gut, which are important for maintaining health.

A very important cell in our immune system is the T-cell (or T lymphocytes) and these cells patrol our system, looking out for anything that could be harmful and, when encountering such, will decide whether to attack.

Cancers actually contain lots of T-cells, but, for some reason they seem not to recognise that the cancer is a threat. Scientists have discovered that T-cells in cancers actually contain a molecule that tells them not to act. Many immunotherapies have focussed on what they call this ‘molecular handshake’ to allow the T-cells to do their job and kill the tumour cells.

However, for pancreatic cancer, the tumours are encased in a thick layer of proteins and cells which act as a barrier to stop the immunotherapy dugs from getting to the tumour and destroying it. This is why immunotherapy trials for pancreatic cancer have, so far, shown disappointing results.

Now a new study by researchers at the Beatson Institute in Glasgow and published in the journal  Cancer Cell1 has found in mouse models and human studies that pancreatic cancer tumours contain a protein (called CXCR2) which protects the tumour by controlling the immune system and preventing it from acting. The scientists have found a way to block the CXCR2 protein using a drug: AZD5069 which has previously been studied in COPD, asthma and is being looked at for head and neck cancers.

By blocking CXCR2, scientists found that there was an initial ‘rush’ of T-cells into the tumour and that this is what can prime the tumours making them more sensitive to chemotherapy drugs as well as immunotherapy agents. Ultimately it is hoped that this will lead to tumour cell death and reduction of the tumour.

While more studies are needed, it now looks like there could be real hope that we can find an effective immunotherapy agent for pancreatic cancer – ultimately unleashing a new weapon against the disease, which is very much needed.

  1. Steele, C., et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma (Cancer Cell 2016) 

Blood glucose 123rfThis week is #NationalDiabetesWeek and social media has been full of interesting facts and hints and tips on how to manage either Type 1 or Type 2 diabetes. What I have noticed though is that no-one has, thus far, mentioned Type 3 diabetes. This hasn’t come as a surprise.

A year before I was diagnosed with operable pancreatic cancer, I was told that I may have Type 2 diabetes. However, I wasn’t overweight, nor did I have a family history of the disease. We now know that it was probably the cancer causing the blood sugar level elevations and this link between new-onset diabetes without weight gain (which can occur 1-3 years before a pancreatic cancer diagnosis) is something that we at Pancreatic Cancer Action are investigating in our research programmes.

Distribution of types of diabetesFor all of these years (nearly 9) I have believed that I have Type 2 diabetes. However, at a recent consultation with my new Diabetologist, I discovered that I have in fact got Type 3c Diabetes.

This I had never heard of before and so went about trying to find out more. I looked at some informed websites including Diabetes UK and found nothing. Not even a mention. And not all of the medical profession has heard of this type of diabetes either – unless they are specialists in this field.

Never being one to give up, I kept on researching. I have since found out that, of all diabetes cases Type 3c makes up about 8%1 – not a lot, but not insignificant either.

distribution of causes of T3c diabetesType 3c Diabetes is usually characterised by the fact that the patient has had all or part of their pancreas resected due to cancer or cystic lesions or other diseases of the pancreas such as pancreatitis and cystic fybrosis.2

Patients often have Pancreatic Exocrine Insufficiency (malabsorption) and are on Pancreatic Enzyme Therapy (PERT) to help them get their nutrients from food.

Initially, my diabetes was considered a ‘side-show’ to the pancreatic cancer and rightly so. Treatment for it started with a combination of gliclazide medication and diet, but over the years my glucose control has declined. Gradually an insulin regime was introduced and, with increasing lack of glucose control (despite being very strict with my diet) the gliclazide has been removed, metformin added (slow release) daily, with insulin injections with meals and snacks and at bedtime.

My diabetes is difficult to manage – I am strict with my carb intake (to the point of being obsessive) and I have taken advantage of new technology in the form of a Freestyle Libre monitor system to help me regularly check my glucose levels without the need to prick my fingers. This is at great expense to me as this system is not funded by the NHS, and each monitor (which lasts 2 weeks) costs about £50.

What is difficult for me is that there is little or no information for patients on how to manage Type 3c diabetes. Do we follow a regime for Type 2 patients or Type 1? Not knowing makes me feel like all of this is a bit of trial and error. I’m lucky to be very closely monitored by my specialists who are helpful in finding strategies I can adopt to get my sugar levels under better control.

I am also lucky that, following my pancreatic cancer diagnosis nearly 9 years ago, my primary health concern is now my diabetes control. And, while it is a nuisance and an intrusion into every-day living, this is something I can live with because I am living many years after being diagnosed with pancreatic cancer – something that happens for only the very few.

Ali Stunt

Founder and Chief Executive

Pancreatic Cancer Action

June 15th 2016

  1. From Cui Y & Andersen DK 2011 Pancreatogenic diabetes: special considerations for management. Pancreatology 11 279–294. Copyright 2011 S Karger AG. Data from Hardt et al. (2008). 
  2. From Cui Y & Andersen DK 2011 Pancreatogenic diabetes: special considerations for management. Pancreatology 11 279–294. Copyright 2011 S Karger AG. Data from Hardt et al. (2008). 

WPCCIt has been an amazingly inspirational couple of days at the very first World Pancreatic Cancer Coalition (WPCC) meeting in Orlando, USA. Over 54 delegates from 24 countries attended and I had the pleasure of meeting some people who I had only previously known through social media or conference call and email exchanges.

There were many more who I was meeting for the very first time – representatives from organisations big and small but, regardless of size, were there for one common purpose: to change the landscape for pancreatic cancer on a global level.

The WPCC has been in development for just under a year under the stewardship of the Steering Committee comprising of Chair, Julie Fleshman, CEO and President of the Pancreatic Cancer Action Network in the USA, myself as co-Vice Chair alongside Alex Ford and Barbara Kenner from the Barbara Kenner Family Research Fund (USA). In this short time we have managed to found the WPCC, set its constitution, develop the branding, develop and launch the website as well as bring together the very first WPCC meeting. Julie Fleshman had assigned some of her team to work on the logistics of this event – and thanks to her and her team, everything worked like clockwork!

One of the key components of the meeting was to have a facilitated brainstorm session to carve out the future priorities and plans for WPCC. This was a very energetic session and there are many key initiatives both for the short and for the longer term that we have taken on board and will publicise once the priorities have been finalised.

As Chair of World Pancreatic Cancer Day, I along with Ruth Fitzgibbons from our creative agency, The Richards Group, presented to WPCC the plans for the Day in 2016 (17th November 2016).

Historically, the World Pancreatic Cancer Day (WPCD) was an initiative of its own and it is from that has provided the springboard for the WPCC. Now, WPCD is one of the key initiatives of the WPCC.

More will be revealed about WPCD to the wider world later, but suffice it to say, the WPCC members were very engaged and excited by the concept we presented and we hope that WPCD on 17th November will be the best EVER!

The WPCC Steering group outlined the governance structure of the Coalition and encouraged members to apply for places on both the main WPCC and WPCD steering committees.

What went down extremely well were the presentations by Coalition members about their activities in their countries. There were many inspiring presentations about initiatives members have developed and run to raise awareness of pancreatic cancer. A lot of learning points and some novel ideas were presented.

We also had presentations on social media strategy and PR relations skills. This was especially beneficial to smaller organisations in the meeting who do not as yet maximise social media on a daily basis.

What we all found very interesting were the scientific presentations by Dr Anirban Maitra and Prof Margaret Tempero (she’s one of PCA’s Scientific Advisory Committee Members).
Both presented good overviews of the research landscape in presentations that weren’t too technical in nature and were easily understood by all.

The key thing I took away from this inaugural WPCC meeting is that there are a lot of people out there across the globe doing amazing work in the pancreatic cancer field. And, while that work may be diverse and different, what we all have in common is a fierce drive and passion to effect change for pancreatic cancer worldwide.

Now we have come together, we will be a collective force to be reckoned with. So, watch this space and if you want to help us, please get behind World Pancreatic Cancer Day on 17th November – it’s going to be a good one!

In November 2015, Pancreatic Cancer Awareness Month, I spent a week educating primary care professionals, scientists and politicians across Europe.  Here is a diary of my adventures:

Friday 6th November: Primary Care Society of Gastroenterology, London

At the Primary Care Society of Gastroenterology, I presented to primary care specialists with an interest in gastroenterology. While they naturally knew about pancreatic cancer, many were informed by the statistics, the causes and risks and some were amazed by the link between new-onset type-2 diabetes not associated with weight gain. This is something that can happen to patients up to 2 years before diagnosis and indeed, happened to me a year before my own diagnosis.

Many were very interested in joining with us in our research project to audit patients in primary care with a diagnosis of type 2 diabetes and a BMI of less than 25. We hope to be able to extend more widely our pilot study in 2016.

Saturday 7th November: The Pancreatic Cancer Forum, Milan

Ali Milan November 2015
Venue for Milan conference

Here I presented to a conference of international scientists and clinicians from across the globe, all with an expertise in pancreatic cancer. It was a large, well-attended conference and the sheer size of the conference hall was a little daunting. I spoke about the European situation for pancreatic cancer: about how it is the fourth leading cause in cancer death in Europe and that there are vast differences in both one and five-year survival rates between countries.

Eurocare 5 5year survival comparisons

Sadly, UK countries fare really badly in these league tables with some of the worst survival rates across the whole of the EU.

I also spoke about the work I have been doing with the EU Multi-Stakeholder Platform on Pancreatic Cancer; now thankfully shortened to just Pancreatic Cancer

The ‘Platform’ is made up of specialists, researchers and patient groups across Europe and I am the UK representative. I told the conference about the three workstreams: Awareness (which I head up), Diagnosis (of which I am a key member) and Registries. I let them know too about the outputs of those three groups – 10 key facts booklet, a symptoms poster (based on the PCA one!), a EU Parliament Declaration, a GP fact-sheet on how to spot pancreatic cancer and an update of the crucial work of the registries project – to consolidate and improve the data we hold on pancreatic cancer, its diagnoses and treatments across the EU.

My talk was very well received and afterwards many clinicians wanted to have copies of my slides for them to communicate the messages in their own countries.

Monday 9th November : European Parliament, Brussels

Ali and MEP Liadh Ní Riada at EU Parliament
Ali and MEP Liadh Ní Riada at EU Parliament

On Monday, I flew in to Brussels to have talks with MEPs about the work of Pancreatic Cancer Europe and also to have a meeting with with the Platform Members. The MEP meetings were to encourage them to support the Platform but also to get them to sign the declaration document to enable increased focus on pancreatic cancer in the European Parliament.

The Pancreatic Cancer Europe meeting was very productive – included the final plans for dissemination of the workstream outputs including translations into 12 languages of the key documents and an introduction of the website ( and an awareness microsite  for WPCD2015.

It was agreed that for 2016 there would be another Workstream for a communications function and this would be run by the European Cancer Patients’ Coalition (ECPC) of which PCA is a member. I will be heading up ECPC’s workgroup for pancreatic cancer in 2016.

There was discussion about the key focus areas for the Platform for 2016 –

  • continuation of communication/dissemination of the workgroup outputs.
  • collation of the European specialist centres for pancreatic cancer on the website (for patient information).
  • It was discussed that a criterion should be set for exactly what constitutes a specialist centre – surgical Whipple’s throughput as one, clinical MDT, relevant palliative care pathways etc – these exist in both the UK and in Germany.
  • Early diagnosis function to work with COST ACTION (EU Pancreas) to work on the key clinical areas and research priorities.
  • Exploration of diabetes mellitus not associated with a metabolic condition (current work of PCA), CA-19-9 and other tumour markers.
  • Palliative care pathways.
  • Access to latest chemotherapy drugs.
  • Encouraging other countries to take part in the registry trials.
  • Patient information and resources.

Also there was discussion surrounding the governance – what type of legal entity should we be working with – as little bureaucracy as possible – clinicians having little time for this.

Wednesday 11th November: K.E.F.I patient group, Athens

I was invited by K.E.F.I – a cancer patient group in Greece to speak at their pancreatic cancer awareness event in Athens to mark World Pancreatic Cancer Day. I was presenting with a specialist surgeon, a specialist oncologist, a specialist nurse and a palliative care consultant. It appears that services for patients are not quite as joined up as they are in the UK and that some patients do not get access to all available treatments, especially palliative care and pain management.

My talk not only included my experience as a patient of pancreatic cancer but was used to disseminate the work of the Multi-Stakeholder Platform to the Greek people.

We were joined by a 10-year survivor of pancreatic cancer who was speaking for the very first time about his diagnosis and treatment. His talk was not only inspiring, but it was extremely emotional and a powerful way to put across the messages about the disease.

It’s been a long and tiring week but well worth it. The encouraging thing is that there is now a community of like-minded people who want to improve pancreatic cancer survival and the patient experience across Europe. This is the beginning but the momentum is building and building fast. I am pleased to be able to play a part in this and take it to the next level. Exciting times are ahead for pancreatic cancer awareness in Europe!

For more information on our campaigning work, please visit:

pansy-in-handWhen I launched Pancreatic Cancer Action in 2010, I chose the pansy to be the logo at the time.  While the Pancreatic Cancer Action logo has been updated, the pansy is still an important party of the charity and to me personally.

It all started with the colour purple. Some, all or none of you may know that purple is the internationally recognised colour for pancreatic cancer. Pancreatic cancer charities in the USA universally adopt the purple colour in their branding. Other pancreatic cancer organisations in the UK and abroad have also adopted purple as their brand colour. We have all seen what pink can do for breast cancer, so maybe purple can do the same for pancreatic cancer? We can but try.

So, we have the colour and we are a charity in the cancer sector. Surely we need a ribbon, don’t we? Well, we could, but the ribbon, to me, doesn’t say anything other than cancer. And while we are an organisation dealing with cancer we are also dealing with other things too such as awareness and survival.

So, back to the pansy. Although it is found in other colours, the pansy fits the purple theme rather nicely and what is even more special is that it flowers during November (the winter variety anyway), which is the month during which we have Pancreatic Cancer Awareness Month.

However, while the pansy ticks the boxes on colour and flowering time, to me the most important symbol of the pansy that it is a living thing. Having a living thing as a logo is important, as I want it in itself to convey a message of hope.

The main focus of our work here at Pancreatic Cancer Action is to raise awareness of the disease and that means shouting about the dire survival rates, the fact that nothing has improved for over 40 years, the underfunding of pancreatic cancer relative to the disease burden and to stop pancreatic cancer from continuing to sit in the shadows of public consciousness. This is all too difficult to hear when you yourself have been diagnosed with the disease. A plague of negative statistics can be upsetting.

The flip side to this is that I too am a pancreatic cancer patient and as a survivor, I want to offer some form of hope to others who have found themselves in the same situation I did 6 years ago in August 2007 when I was diagnosed. And I continue to campaign so that more people will be able to have the same outcome that I have had.

Hope when there seems none is difficult to maintain unless there are advocates promoting the potential of hope.

The problem is, we in the pancreatic cancer world are short on survivors to provide that advocacy role (as so many have successfully done for breast cancer and recently prostate cancer) as only 3 to 4 % of the 8,000 or so people in the UK newly diagnosed with pancreatic cancer each year will survive 5 years. Randy Pausch (the American university professor who sadly died of pancreatic cancer in July, 2008) noted, “There aren’t celebrity spokespeople for the disease because too few survive long enough to take on that role.”

Celebrity or not, that campaign mantle role must be filled in order to awaken society to the realities of this disease – the 5th most common cause of cancer death in the UK and allow for pancreatic cancer, its risks, symptoms and prognosis to be familiar to us all.

If you have been diagnosed with pancreatic cancer and want to take on an advocacy role by sharing your story on our website or in the press, please get in touch via our contact us form